A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines.
In previous studies, combinations of immunotoxins reactive with different cell-surface antigens have exerted additive cytotoxicity against tumor cells in culture. In this report we describe a combination of 2 immunotoxins that produce synergistic cytotoxic activity. Recombinantly derived ricin A chain (RTA) was conjugated with murine monoclonal antibodies (MAbs) 317G5, 260F9, 454A12 and 741F8 that bound to cell-surface determinants of 42, 55, 180 (transferrin receptor) and 185 kDa (HER-2/neu) expressed by the SKBr3 human breast-cancer cell line. When inhibition of clonogenic growth was measured in a limiting dilution assay, the combination of 260F9-RTA and 454A12-RTA produced synergistic cytotoxic activity against SKBr3 and 2 other breast-cancer cell lines. All other combinations produced only additive inhibition of clonogenic growth. Simultaneous binding of 260F9 and 454A12 was not supra-additive, but sub-populations of cells which lacked one or the other antigen could be detected. Kinetic studies of internalization, using antibodies conjugated with gold particles, indicated that 454A12 remained within peripheral endosomes for a longer interval in the presence of 260F9. This change in the traffic of the transferrin receptor may contribute to synergy between 260F9-RTA and 454A12-RTA.
Crews
J R
JR
Department of Medicine, Duke University Medical Center, Durham, NC 27710.
Maier
L A
LA
Yu
Y H
YH
Hester
S
S
O'Briant
K
K
Leslie
D S
DS
DeSombre
K
K
George
S L
SL
Boyer
C M
CM
Argon
Y
Y
D000911:Antibodies, Monoclonal / Q000378:metabolism; D000951:Antigens, Neoplasm / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology; D004357:Drug Synergism; D004705:Endocytosis; D006046:Gold; D006801:Humans; D000922:Immunotoxins / Q000008:administration & dosage* / Q000627:therapeutic use; D007700:Kinetics; D008854:Microscopy, Electron; D009856:Oncogene Proteins, Viral / Q000276:immunology; D018719:Erb-b2 Receptor Tyrosine Kinases; D011990:Receptors, Transferrin / Q000276:immunology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012276:Ricin / Q000008:administration & dosage* / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D006046:Gold; D000922:Immunotoxins; D009856:Oncogene Proteins, Viral; D018719:Erb-b2 Receptor Tyrosine Kinases; D011990:Receptors, Transferrin; D011994:Recombinant Proteins; D012276:Ricin